MYALEPTA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania, UK.

Active ingredients

The drug MYALEPTA contains one active pharmaceutical ingredient (API):

1	Metreleptin UNII TL60C27RLH - METRELEPTIN
	Metreleptin mimics the physiological effects of leptin by binding to and activating the human leptin receptor, which belongs to the Class I cytokine family of receptors that signals through the JAK/STAT transduction pathway.
	Read more about Metreleptin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MYALEPTA Powder for solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AA07		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AA Amino acids and derivatives
Discover more medicines within A16AA07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1777271, 1777282, 1802315, 1802326, 1802337, 1802348
FR	Base de données publique des médicaments	60446726, 67974594, 69994784
GB	Medicines & Healthcare Products Regulatory Agency	374481, 374515, 374521
IT	Agenzia del Farmaco	046926010, 046926022, 046926034, 046926046, 046926059, 046926061
LT	Valstybinė vaistų kontrolės tarnyba	1086043, 1086044, 1086751, 1086752, 1086753, 1086754
PL	Rejestru Produktów Leczniczych	100409306, 100418080, 100418096
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67091001, W67091002, W67092001, W67092002, W67093001, W67093002